BioLab Holdings

Executive Summary

BioLab Holdings is a privately held medical manufacturing company headquartered in Miami, Florida, dedicated to advancing wound care through regenerative medicine. Founded in 2018, the company develops, manufactures, and commercializes products derived from amniotic membrane and synthetic matrices, targeting chronic and hard-to-heal wounds. Its mission emphasizes scientific rigor, compassion, and collaboration. With a focus on optimizing the standard of care, BioLab aims to address the significant unmet need in wound management, particularly for diabetic ulcers and surgical wounds. The company operates in the tissue engineering category and leverages its expertise to bring innovative biological dressings and grafts to market. As a private entity, BioLab Holdings does not disclose financials publicly, but its presence in the regenerative medicine space positions it for potential growth driven by an aging population and rising diabetes prevalence.

Upcoming Catalysts (preview)

• Q3 2026FDA 510(k) Clearance for a Next-Generation Amniotic Membrane Product70% success
• Q4 2026Strategic Distribution Partnership with a Major Wound Care Provider60% success
• Q2 2027Series B Funding Round to Support Clinical Trials and Commercial Expansion75% success